camptothecin has been researched along with hki 272 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Al-Ahmadie, H; Almassi, N; Alvim, R; Audenet, F; Bagrodia, A; Chen, Z; Clinton, TN; Cocco, E; Coleman, JA; Dason, S; Dong, Y; Elzein, A; Gao, J; Gao, SP; Gordon, B; Hakimi, AA; Hanrahan, AJ; Hsieh, JJ; Hu, W; Hughes, C; Iyer, G; Jebiwott, S; Kim, K; Mohan, V; Murray, K; Nagar, K; Ostrovnaya, I; Penson, A; Pietzak, EJ; Rosenberg, JE; Sagi, I; Santin, AD; Scaltriti, M; Solit, DB; Vargas, HA; Watson, PA; Wong, N | 1 |
| Gelmon, KA; Tesch, ME | 1 |
| Dixon, JM; Gray, M; Kay, C; Martínez-Pérez, C; Meehan, J; Turnbull, AK; Webber, V | 1 |
2 review(s) available for camptothecin and hki 272
| Article | Year |
|---|---|
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2020 |
Current trends in the treatment of HR+/HER2+ breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Receptor Antagonists; Female; Humans; Immunoconjugates; Mastectomy; Molecular Targeted Therapy; Neoadjuvant Therapy; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2021 |
3 other study(ies) available for camptothecin and hki 272
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts.
Topics: Aged; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy; Camptothecin; Carcinoma, Transitional Cell; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Variation; High-Throughput Nucleotide Sequencing; Humans; Immunoconjugates; Interleukin Receptor Common gamma Subunit; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Transplantation; Phenotype; Precision Medicine; Prospective Studies; Quinolines; Retrospective Studies; Sequence Analysis, RNA; Trastuzumab; Urinary Bladder Neoplasms; Urothelium | 2020 |